Samuel Duffey
Chief Executive Officer at Analytica International, Inc.
Net worth: 11 000 $ as of 2024-03-30
Profile
Samuel S.
Duffey currently works at Analytica International, Inc., as Chief Executive Officer and Vycellix, Inc., as Executive VP, General Counsel & Director.
Mr. Duffey also formerly worked at BioVest International, Inc., as President & Chief Executive Officer in 2013, Accentia Biopharmaceuticals, Inc., as President, CEO & General Counsel from 2012 to 2013, Uniroyal Global Engineered Products, Inc., as Non-Executive Chairman from 2000 to 2003, Flashpoint International, Inc., as Non-Executive Chairman from 2001 to 2004, US Securities & Exchange Commission, as Staff Trial Attorney, and Hopkins Capital Group, as General Legal Counsel.
Mr. Duffey received his undergraduate degree and graduate degree from Drake University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-08-02 | 10,000 ( 0.07% ) | 11 000 $ | 2024-03-30 |
Samuel Duffey active positions
| Companies | Position | Start |
|---|---|---|
Analytica International, Inc.
 Analytica International, Inc. Miscellaneous Commercial ServicesCommercial Services Analytica International, Inc. provides analytical and consulting services to the biopharmaceuticals industry. The company was founded on October 28, 2005 and is headquartered in New York, NY. | Chief Executive Officer | - |
Vycellix, Inc.
 Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Director/Board Member | - |
Former positions of Samuel Duffey
| Companies | Position | End |
|---|---|---|
BioVest International, Inc.
 BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | President | 2013-07-14 |
| ACCENTIA BIOPHARMACEUTICALS INC | President | 2013-02-19 |
| Flashpoint International, Inc. | Chairman | 2004-04-30 |
| UNIROYAL GLOBAL ENGINEERED PRODUCTS, INC. | Chairman | 2003-08-31 |
| US Securities & Exchange Commission | Corporate Officer/Principal | - |
Training of Samuel Duffey
| Drake University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| UNIROYAL GLOBAL ENGINEERED PRODUCTS, INC. | Electronic Technology |
| Private companies | 7 |
|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology BioVest International, Inc. develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. The firm continued development, commercialization, manufacture and sale of AutovaxID and other instruments and disposables; and the commercial sale and production of cell culture products and services. The company was founded in 1981 and is headquartered in Tampa, FL. | Health Technology |
Accentia Biopharmaceuticals, Inc.
 Accentia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Accentia Biopharmaceuticals, Inc. engages in the commercialization of patent-protected disruptive healthcare technologies. It offers products under the BiovaxID., Revimmune, and SinuNase brands. The company was founded in 2002 and is headquartered in Tampa, FL. | Health Technology |
| Flashpoint International, Inc. | Finance |
| US Securities & Exchange Commission | Finance |
Analytica International, Inc.
Analytica International, Inc. Miscellaneous Commercial ServicesCommercial Services Analytica International, Inc. provides analytical and consulting services to the biopharmaceuticals industry. The company was founded on October 28, 2005 and is headquartered in New York, NY. | Commercial Services |
Hopkins Capital Group
 Hopkins Capital Group Investment ManagersFinance Hopkins Capital Group(Hopkins Capital) is a private equity firm founded in 1999 by Frank E. O'Donnell. The firm is headquartered in Tampa, Florida. | Finance |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Health Technology |
- Stock Market
- Insiders
- Samuel Duffey
